Figure 4.

Rankogram. This diagram shows the probability that the treatment is best for CD recurrence. None of the treatments appear clearly superior to others when all the outcomes are considered together. There does not seem to be much correlation between a treatment being best in reducing blood transfusion and a treatment being best in reducing recurrent events. PLA, placebo; untreated, blank control group; MSLZ, mesalazine; BDND, budesonide; AZA, azathioprine; IFX, infliximab; ADA, adalimumab; TW, Tripterygium wilfordii; LGG, Lactobacillus GG.